Literature DB >> 15505421

Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T cells.

J H Miller1, B Rouwé, T N Gaitanos, K A Hood, K P Crume, B T Bäckström, A C La Flamme, M V Berridge, P T Northcote.   

Abstract

Peloruside A (peloruside), a compound isolated from the marine sponge Mycale hentscheli , inhibits growth of human (HL-60) and mouse (32D-ras) myeloid leukemic cells, as well as non-transformed 32D cells. Using the MTT cell proliferation assay and trypan blue dye exclusion tests, little difference was seen in growth inhibition between 32D and 32D- ras cells; however, peloruside was more cytotoxic to the oncogene-transformed cells. Peloruside also blocked 32D- ras cells more readily in G2/M of the cell cycle, leading to apoptosis. Annexin-V/propidium iodide staining of 32D and 32D- ras cells showed that 1.6 microM peloruside induced significant cell death by 36 hours in 32D cells (16% survival), but to comparable levels as early as 14 hours in 32D- ras cells (11% survival). There was no evidence for activation of either of the initiator caspases-8 or -9 by 0.1 microM peloruside following 12 hours of exposure. Peloruside inhibited T cell proliferation and IL-2 and IFN gamma production in both the mixed lymphocyte reaction and following CD3 cross-linking, and this effect was shown to be a non-specific cytotoxic effect. It is concluded that peloruside preferentially targets oncogene-transformed cells over non-transformed cells by inducing transformed cells to undergo apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505421     DOI: 10.1023/B:APPT.0000045789.54694.cf

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  9 in total

1.  Toward the synthesis of (+)-peloruside A via an intramolecular vinylogous aldol reaction.

Authors:  Jeffrey A Gazaille; Joseph A Abramite; Tarek Sammakia
Journal:  Org Lett       Date:  2011-12-12       Impact factor: 6.005

2.  Achmatowicz Reaction and its Application in the Syntheses of Bioactive Molecules.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  RSC Adv       Date:  2016-11-24       Impact factor: 3.361

3.  Rapid access to conformational analogues of (+)-peloruside A.

Authors:  Zhiming Zhao; Richard E Taylor
Journal:  Org Lett       Date:  2012-01-11       Impact factor: 6.005

Review 4.  Strategies for the synthesis of the novel antitumor agent peloruside A.

Authors:  David R Williams; Partha P Nag; Nicolas Zorn
Journal:  Curr Opin Drug Discov Devel       Date:  2008-03

Review 5.  Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.

Authors:  John H Miller; A Jonathan Singh; Peter T Northcote
Journal:  Mar Drugs       Date:  2010-03-31       Impact factor: 5.118

6.  Total synthesis of (-)-18-epi-peloruside A: an alkyne linchpin strategy.

Authors:  Barry M Trost; David J Michaelis; Sushant Malhotra
Journal:  Org Lett       Date:  2013-10-04       Impact factor: 6.005

7.  Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells.

Authors:  Arun Kanakkanthara; Pisana Rawson; Peter T Northcote; John H Miller
Journal:  Pharm Res       Date:  2012-05-15       Impact factor: 4.200

8.  Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells.

Authors:  Anja Wilmes; Pisana Rawson; Lifeng Peng; Danyl McLauchlan; Peter T Northcote; T William Jordan; John H Miller
Journal:  Invest New Drugs       Date:  2010-01-27       Impact factor: 3.850

9.  First Report on Chitin in a Non-Verongiid Marine Demosponge: The Mycale euplectellioides Case.

Authors:  Sonia Żółtowska-Aksamitowska; Lamiaa A Shaala; Diaa T A Youssef; Sameh S Elhady; Mikhail V Tsurkan; Iaroslav Petrenko; Marcin Wysokowski; Konstantin Tabachnick; Heike Meissner; Viatcheslav N Ivanenko; Nicole Bechmann; Yvonne Joseph; Teofil Jesionowski; Hermann Ehrlich
Journal:  Mar Drugs       Date:  2018-02-20       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.